Orphan drugs and the NHS: should we value rarity?

BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016.

Abstract

The growing number and costs of drugs for rare diseases are straining healthcare budgets. Decisions on funding these treatments need to be made on a sound basis

Publication types

  • Review

MeSH terms

  • Cost-Benefit Analysis
  • Drug Costs
  • Health Status
  • Humans
  • Orphan Drug Production* / economics
  • Rare Diseases / drug therapy*
  • State Medicine / economics
  • Treatment Outcome